CMS Opens a Narrower Door for palliative care, Then Asks What Medicare Should Cover Next
CMS moved on two fronts this summer, and the difference between them matters in practice. One action clarified that skilled palliative care services can be furnished and billed under the existing Medicare home health benefit for eligible patients with serious illness. The other took the more ambitious step of asking whether Medicare should create a broader community-based palliative care benefit outside hospice altogether.
The first move changes interpretation; the second could change access.
Home health and palliative care overlap only partially, and that mismatch has shaped the policy debate for years. Home health generally assumes a patient is homebound, has a discrete skilled need, and may improve with a structured episode of care. Serious-illness populations often look very different. Many need repeated clinical touchpoints, help with symptom control, advance care planning, deprescribing, and coordination among multiple clinicians even when no single wound, infusion, or therapy fits the traditional home health frame.
Why the Home Health Framework Fits Poorly for Serious Illness
The home health clarification is real, but it is not a new benefit. It sits inside a payment structure designed around restoration and measurable improvement, two concepts that can clash with the needs of patients whose illnesses are progressive or fluctuating. In palliative care, the goal is often not recovery in the conventional sense. It is relief, alignment of treatment with patient goals, better symptom management, and fewer preventable crises.
Patients with advanced disease frequently do not have a single “skilled need” that satisfies the older benefit design. They may need a nurse practitioner, physician, social worker, chaplain, or care coordinator to address pain, dyspnea, anxiety, medication burden, caregiver strain, and transitions after an emergency visit. Those services are clinically distinct from hospice and can occur alongside disease-directed therapy, which is why the timing of access matters. If the only practical Medicare pathway is built for improvement and discharge, many patients will still fall through the cracks.
CMS Asked the Questions That Will Decide Access
The physician fee schedule request for information goes much further. CMS asked whether eligibility for a community-based palliative care benefit should depend on terminal prognosis or instead on function, symptoms, or caregiver burden. It also asked what the essential elements of care should include: continuity with a designated team member, timely clinical support, comprehensive assessment of symptoms and caregivers, coordination with treating physicians, and prompt follow-up after an emergency visit or discharge.
Those are not administrative details. They define the biology of the service delivery model.
If the benefit rewards continuity, then clinicians can intervene before pain escalates, before delirium or dyspnea triggers an ambulance call, and before medication regimens become unsafe or overwhelming. If quality measures are built around symptom relief, care coordination, and post-discharge response, the program could support the kind of longitudinal management that advanced illness actually requires. If eligibility is too narrow, the benefit may remain inaccessible until patients are already near the hospice threshold, which defeats much of the point of community-based palliative care.
The request for information also asked about fraud and abuse protections. That issue will shape any future design because Medicare has to balance broader access with safeguards that prevent vague care plans from becoming an uncontrolled billing channel. The policy challenge is to define this care clearly enough to be usable and broad enough to be clinically meaningful.
New Jersey Has Become the Real-World Test Case
CMS appears to be waiting for proof before making a national commitment, and New Jersey now serves as the most relevant test. The state’s Medicaid community-based palliative care benefit launched on April 1, 2026. It reimburses an interdisciplinary team on a per-member-per-month basis for seriously ill patients receiving ongoing treatment, and it does not require a terminal prognosis.
The design is important because it tracks how palliative care is actually delivered in the community. A per-member-per-month model can support the longitudinal work that fee-for-service often ignores: repeated outreach, family meetings, cross-setting coordination, symptom surveillance, and rapid response after deterioration. It also raises hard operational questions. Will hospitals and community physicians refer appropriate patients? Will clinicians have enough contact with those patients to manage symptoms before they spiral? Will patients report a better experience, and will utilization patterns shift in a way that justifies broader adoption?
Bedside Need, Policy Design, and Federal Caution Are Colliding
For physicians, the policy signal is mixed but meaningful. CMS has acknowledged that serious illness can require structured support well before hospice eligibility, and it has invited direct input on how Medicare should respond. At the same time, the agency stopped short of creating a national benefit. The result is a narrow clarification inside home health, paired with an open-ended question about whether Medicare should build something larger and more durable.
That gap is where the clinical argument now lives. Community-based palliative care is meant for patients who are still pursuing treatment but need more than episodic specialist visits can provide. It addresses inadequate symptom control, repeated acute-care use, and the absence of coordinated conversations about what matters most to patients and families. When those services are delivered consistently, they can keep care aligned with patient goals and reduce the kind of emergency-driven care that often marks advanced illness.
Physician response will influence whether CMS treats this as an isolated adjustment or the first step toward a real benefit. The New Jersey experience will matter as well, because federal policymakers rarely move on intent alone. They move when a model shows it can be referred to, staffed, measured, and sustained without collapsing under its own design.
For now, Medicare has opened a policy debate that clinicians have wanted for years. The unresolved question is not whether serious-illness patients need community-based palliative care. It is whether the payment structure will finally match the care they already require.